Halozyme Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.21% of Halozyme Therapeutics' common stock as of March 31, 2026.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 10.2% Stake in Halozyme Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 10.2% beneficial ownership stake in Halozyme Therapeutics, Inc. as of June 30, 2025.
NASDAQ
State Street Corporation has reported a passive 4.9% beneficial ownership stake in Halozyme Therapeutics Inc., holding 6,053,007 shares of common stock as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 13.1% Passive Stake in Halozyme Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 13.1% beneficial ownership stake in Halozyme Therapeutics, Inc. as of March 31, 2025.